The American laboratory Pfizer announced on Friday that it is lowering its forecasts for the entire 2023 fiscal year due to lower than expected sales of products (vaccines and drugs) related to Covid-19, reports AFP.

Paxlovid is Pfizer’s antiviral drug against COVIDPhoto: Dreamstime.com

Its sales will be between $58 billion and $61 billion, compared with the $67 billion and $70 billion previously forecast, and net earnings per share, the market’s guidance, will be between $1.45 and $1.65 (previously between $3.25 and $3.45).

The company said it spent $5.5 billion on inventory write-downs in the third quarter.

Paxlovid, an antiviral drug for the treatment of COVID-19 developed by Pfizer, will arrive in Romania soon. Previously, only the antiviral drug Molnupiravir, developed by Merck, was available in Romania for the treatment of COVID-19. (photo: Dreamstime.com)

  • Read also: The story of a researcher who risked her career to develop a messenger RNA vaccine / How the RNA vaccine against COVID-19 works